OncoMatch/Clinical Trials/NCT06621563
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
Is NCT06621563 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for solid tumors.
Treatment: HS-20117 combined HS-20093 · HS-20117 combined Platinum-containing chemotherapy · HS-20117 combined HS-20093 and 5-FU · HS-20117+CAPEOX · HS-20117+FOLFIRI · HS-20117+mFOLFOX6 — HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: MET inhibitor
Any anticancer therapy targeting MET, including TKIs, antibodies or antibody-drug conjugates.
Cannot have received: EGFR-targeted monoclonal or bispecific antibody
Monoclonal or bispecific antibodies targeting EGFR.
Cannot have received: systemic anti-cancer treatment
Systemic anti-cancer treatment (Cytotoxicities and anti-cancer Traditional Chinese medicine or TKIs) within 2 weeks prior to the first dose of HS-20117.
Cannot have received: investigational anti-cancer drugs or antibodies or ADCs
Investigational anti-cancer drugs or antibodies or ADCs within 4 weeks prior to the first dose of HS-20117.
Cannot have received: local radiotherapy
Local radiotherapy within 2 weeks prior to the first dose of HS-20117, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of HS-20117.
Cannot have received: major surgery
Major surgery within 4 weeks prior to the first dose of HS-20117.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06621563 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MET inhibitor, EGFR-targeted monoclonal or bispecific antibody, systemic anti-cancer treatment disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify